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Background: Since the presence of fetal DNA was discovered in maternal blood, different investigations have focused on non-invasive prenatal
diagnosis. The analysis of fetal DNA in maternal plasma may allow the diagnosis of fetuses at risk of cystic fibrosis (CF) without any risk of fetal
loss. Here, we present a new strategy for the detection of fetal mutations causing CF in maternal plasma.
Methods: We have used a mini-sequencing based method, the SNaPshot®, for fetal genotyping of the paternal mutation in maternal blood from
three pregnancies at risk of CF.
Results: The paternal mutation was detected in the analysis of plasma samples from cases 1 and 3 but not in case 2. Results of a posterior
conventional molecular analysis of chorionic biopsies were in full agreement with those obtained from analysis of the plasma samples.
Conclusions: The knowledge about the inheritance of the paternal mutation in a fetus may avoid the conventional prenatal diagnosis in some
cases. The SNaPshot® technique has been shown to be a sensitive and accurate method for the detection of fetal mutations in maternal plasma. Its
ease handling, rapid and low cost makes it appropriate for a future routine clinical use in non-invasive prenatal diagnosis of cystic fibrosis.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Fetal mutation; Non-invasive prenatal diagnosis; Cystic fibrosis; Mini-sequencing method1. Background
Prenatal diagnosis of cystic fibrosis (CF) (OMIM #279100)
is currently recommended to those couples in which both
members are known to be carriers of a CF mutation. However,
the current obstetric procedures to perform the prenatal☆ The present work was presented as an oral communication titled “Prenatal
Diagnosis of Cystic Fibrosis” as part of the Scientific Program of the Circulating
Nucleic Acids in Plasma/Serum V (CNAPS V) conference which took place in
Moscow (Russian Federation) in August, 23–27, 2007.
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1569-1993/$ - see front matter © 2008 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2008.05.006diagnosis of an inherited monogenic disorder imply the
invasion of the intrauterine environment, which entails a
significant risk of miscarriage (0.5–1%).
Non-invasive prenatal diagnosis (NIPD) is based on the study
of circulating cell-free fetal DNA (ccffDNA) present in maternal
blood [1]. This non-invasive diagnostic method presents great
advantages, but also some limitations. The great advantage is the
absence of fetal loss, thus allowing the performance of a safe
genetic study of the fetus. On the other hand, two important
limitations to be considered are the coexistence of this ccffDNA
with circulating DNA of maternal origin and the low percentage
of the total DNA that it represents (3–6%) [2–4]. The presence
of maternal DNA in the plasma sample limits the diagnosis to the
detection of paternally-inherited fetal sequences that ared by Elsevier B.V. All rights reserved.
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gies are thus required for these non-invasive studies due to the
low levels of fetal DNA and the success in detecting fetal alleles
strongly depends on which technique is chosen.
Since the presence of fetal DNA in maternal blood was
reported in 1997 [1], several investigations have focused on
developing different prenatal studies using ccffDNA [5–14].
Two investigations, fetal gender assessment and Rh fetal
determination, are beginning to be translated into routine
clinical use [15,16]. However, other studies that are still in the
research setting, such us the prenatal diagnosis of fetal
mutations or aneuploidies [17,18,19–21], may also be incorpo-
rated into clinical diagnostic algorithms in future years.
At present, different sensitive and easy handling technolo-
gies are being developed for the detection of SNPs. As these
methodologies are designed to detect single-base changes, we
hypothesised about the possible application of these techniques
for the detection of paternally-inherited fetal mutations in
maternal plasma. The clinical basis of this hypothesis was
aimed at those pregnancies at risk of having a fetus affected with
a recessive disease such cystic fibrosis. NIPD can thus offer an
alternative to these patients through the study of a paternal
mutation in maternal plasma. Knowledge of the inheritance of a
paternal mutation by the analysis of maternal plasma could
avoid undergoing invasive procedures when the mutation
carried by the father is excluded.
We looked for a methodology which will be appropriate to
use for the future clinical diagnosis of paternally-inherited fetal
mutations and we opted for the use of a mini-sequencing-based
methodology, referred to as SNaPshot® (Applied Biosystems).
We chose this technique because of its easy and rapid use,
sensitivity, and low cost. In the present work, fetuses from three
pregnancies at risk of cystic fibrosis were genotyped for the
mutation carried by their fathers by this method.
2. Methods
This study was performed on plasma samples collected from
three pregnancies at risk of having a fetus affected with cystic
fibrosis. Participants came to our service to undergo chorionic
biopsy because of the risk of CF and they were asked to
participate in this research study.
In the three pregnancies, both parents were carriers of a
different CF mutation in the Cystic Fibrosis TransmembraneTable 1
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Primer sequences used for amplification are also listed.Conductance Regulator (CFTR) gene and, in addition,
the paternal mutation was distinct in each case as follows:
p.Arg668Cys (case 1) and p.Lys710ter (case 2), both located in
exon 3 of the CFTR gene, and p.Tyr1092ter (case 3) located in
exon 17b of the CFTR gene (Table 1).
2.1. Sample collection
Twenty millilitres of maternal blood from each pregnant
woman were collected in EDTA tubes, under informed consent
and in accordance with the Helsinki Declaration. Samples were
obtained during the 12th week of gestation before chorionic
biopsy was performed. In case 3, an additional maternal blood
sample was obtained during the 15th week of gestation.
Nine millilitres of peripheral blood from the parents of each
fetus was collected in EDTA tubes under informed consent.
2.2. Plasma sample processing
Samples were processed within 24 h of blood collection.
Blood samples were centrifuged at 1600 rpm for 10 min in the
original collection tube. Plasma was collected, divided in 1-mL
aliquots, and centrifuged at 14,000 rpm for 10 min. Both
centrifugations were carried out at room temperature. The
supernatant was removed from each aliquot and stored at
−20 °C.
2.3. DNA extraction
Plasma samples were thawed at room temperature. Two
millilitres of maternal plasma from each pregnant woman was
used for DNA extraction using the QIAamp DNA Blood
MiniKit (QIAGEN) according to the protocol previously
reported [14].
DNA from the parents of each pregnancy was extracted from
350 μl of peripheral blood by the BioRobot EZ1 (QIAGEN).
2.4. PCR controls
For each mutation studied, positive and negative controls
were used. In each case, DNA from the father was used as the
heterozygous control (positive control) and maternal DNAwas










Fig. 1. Electropherograms of the parental DNA controls (Mother, as negative control and Father, as positive control) and the maternal plasma samples (Plasma) of each case. x axis, computed length of PCR products in
base pairs as determined automatically by the use of internal lane standard; y axis, fluorescence intensities in arbitrary units. The arrows show the peak which represents the mutation. Case 1: Wild-type and mutated
nucleotide (paternal mutation) are present in the plasma sample. Case 2: The electropherogram of the plasma sample is similar to the one presented by the maternal DNA, only the wild-type nucleotide is present. Case 3:
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PCR was carried out in a GeneAmp PCR System 2700
thermal cycler (Applied Biosystems). For the amplification,
16.3 μl of DNA from the plasma samples and 100 ng of DNA
from the controls were used as templates. PCR conditions in
each case were as follows:
2.5.1. PCR for exon 13 (cases 1 and 2)
The final volume was 25 μl, containing 7.5 pmol of each
primer (forward: 5′-TGATTCTTTCGACCAATTTAGTG-3′;
reverse: 5′-ATCTGGTACTAAGGACAG-3′; Applied Biosys-
tems), 1× PCR buffer with 2.5 nM MgCl2 (Roche), 200 μM of
each deoxynucleotide (Invitrogen), and 1 U of FastStart Taq
DNA polymerase (Roche). After an initial incubation at 95 °C
for 5 min, the reaction was cycled for 30 s at 95 °C, 20 s at
55 °C, and 50 s at 74 °C for 40 cycles, followed by a final
extension of 5 min at 74 °C (Table 1).
2.5.2. PCR for exon 7b (case 3)
The final volume was 24 μl, containing 10 pmol of each
primer (forward: 5′-GGAGTCCAATTTTCACTCATCTTGT-
3′; reverse: 5′-CCTGTTGTTAAAATGGAAATGAAGG-3′;
Applied Biosystems), 1× PCR buffer with 2.5 nM MgCl2
(Roche), 200 μMof each deoxynucleotide (Invitrogen), and 1 U
of FastStart Taq DNA polymerase (Roche). After an initial
incubation at 94 °C for 5 min, the reaction was cycled for 40 s at
94 °C, 40 s at 58 °C, and 45 s at 72 °C for 40 cycles, followed by
a final extension for 7 min at 72 °C (Table 1).
Excess primers and dNTPs were removed by the addition of
4μl of ExoSAP-IT (USB) to 10μl of PCR product and incubating
the mixture at 37 °C for 15 min, followed by 80 °C for 15 min.
2.6. Mini-sequencing reaction
The SNaPshot® Multiplex System (Applied Biosystems) is a
mini-sequencing method based on a fluorescent-labelled
dideoxy single-base extension of an unlabeled oligonucleotide
primer or primers which hybridise upstream to the SNP site.
The four different ddNTPs (ddCTP, ddTTP, ddATP, and
ddGTP) contained in the mini-sequencing reaction mix are
labelled with a distinct fluorochrome. The only dideoxinucleo-
tide incorporated to this primer during the reaction indicates the
nucleotide present at the mutation site.
A specific primer was designed for each mutation studied.
Eight μl of purified PCR product from the plasma samples and
3 μl from the controls were used as a template. The reaction was
carried out in a final volume of 20 μl, containing 10 μl of
SNaPshot® Multiplex Ready Reaction Mix (Applied Biosystems)
and 20 pmol of the specific unlabeled primer, as follows: primer for
case 1: 5′-AATTCAATCCTAACTGAGACCTTACAC-3′; primer
for case 2: 5′-TTCTCAATCCAATCAACTCTATACGA-3′; and
primer for case 3: 5′-ACATACTGCCAACTGGTTCTTGTA-3′
(Table 1). The reactionwas cycled for 10 s at 96 °C, 5 s at 50 °C, and
30 s at 60 °C for 30 cycles.
Excess nucleotides were removed by the addition of 2 μl
(1 U/μl) of shrimp alkaline phosphatase enzyme and 2.4 μl of10× SAP Buffer (USB), and incubating the mixture at 37 °C for
1 h followed by 75 °C for 15 min.
Purified product from control DNAs was diluted 1:10 before
being charged in the automated sequencer. For the analysis, 8 μl
of purified product from the plasma samples and 1 μl from the
controls were mixed with 12 μl of Hi-Di formamide (Applied
Biosystems) and 0.5 μl of GeneScan 120Liz size standard
(Applied Biosystems). The analysis was carried out in an
ABI3130xl Genetic Analyzer (Applied Biosystems) using
GeneMapper software (Applied Biosystems).
3. Results
The analysis of the positive and negative control DNAs in
each pregnancy (parental DNAs) revealed distinct electropher-
ograms. The maternal DNA showed a electropherogram with a
unique peak corresponding to the wild-type nucleotide in the
mutation site. However, the paternal DNA, as heterozygous
control, showed a peak corresponding to the mutation (paternal
marker) in addition to the peak associated to the wild-type
nucleotide (Fig. 1).
3.1. Plasma samples
In the analysis of the maternal plasma samples collected
from the three pregnancies, the peak corresponding to the wild-
type nucleotide in the mutation site was present because of the
existence of maternal DNA in the sample. However, the
paternal marker was only observed in cases 1 and 3 (Fig. 1). The
existence of the paternal mutation in the plasma samples
collected from cases 1 and 3 can only be explained for its fetal
origin. In these two cases, the height of the peak associated to
the mutation was much lower than the one associated to the
wild-type nucleotide because of the low amount of fetal DNA
present in the sample. In case 3, a second maternal blood sample
was collected in the second trimester of the gestation. In the
analysis of this second sample a higher peak corresponding to
the paternally-inherited fetal mutation was observed.
In case 2, the electropherogram pattern observed in the
analysis of the plasma sample was the same as the one produced
by the negative control (maternal DNA). The peak associated
with the mutation carried by the father and shown by the
positive control was not present in the plasma sample (Fig. 1).
Posterior conventional molecular analysis of the biopsies
revealed that only in cases 1 and 3 had the fetuses inherited the
paternal mutation. Therefore, in all three cases studied, the
analysis of the paternal mutation in the maternal plasma was in
accordance with those results obtained in the conventional
prenatal diagnosis.
4. Discussion
The prenatal diagnosis of cystic fibrosis is currently
performed in those couples at risk of having an affected fetus;
however, it carries a risk of miscarriage. NIPD, based on the
study of ccffDNA present in maternal plasma, is an encouraging
alternative methodology to provide information regarding the
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ago, all publications pertaining to NIPD reported the hypothe-
tical clinical applications of these studies. Currently some of the
studies carried out by this methodology such us the fetal gender
assessment or fetal Rh determination in maternal blood have
already been translated into clinical routine [15,16]. Hence,
some of the studies based on the use of fetal DNA in maternal
blood are at present a real alternative offered in the genetic
services for some patients.
Our group has been consistently working toward the direct
clinical application of NIPD [7–9,14,16,22]. In this work, we
hypothesized the application of a methodology designed for
SNP detection to the diagnosis of fetal mutations in maternal
plasma. In fetuses at risk of a recessive disease such as cystic
fibrosis, knowledge of the inheritance of the paternal mutation
in the first trimester of gestation provides additional information
to be considered for genetic counselling. In the case of fetuses at
risk of cystic fibrosis, exclusion of the paternal mutation in the
maternal plasma would indicate that the fetus was, at worst, a
carrier of the maternal mutation. Therefore, conventional
invasive procedures could be withheld. However, if the paternal
mutation was present, conventional prenatal diagnosis would be
recommended in order to determine the fetal status with respect
to the maternal mutation. At present, the existence of maternal
DNA in the maternal plasma sample limits this study to those
couples in which both members are carriers of different CF
mutations. However the highest mutation heterogeneity
reported in European and Middle Eastern areas would make
this diagnosis highly applicable in those populations [23,24]. In
Spain, the frequency of the DeltaF508 mutation is lower than in
other Caucasian populations [25]. As a reference laboratory for
the study of CF, our experience in the last eight years reflects
that approximately 56% of the prenatal diagnoses were
performed in couples in which both members were carriers of
a different CF mutation. Therefore, this non-invasive method
would be applicable in this percentage of pregnancies at risk.
Pursuing the future clinical application of this non-invasive
approach, we have selected a new technology based on a mini-
sequencing reaction, the so-called SNaPshot® (Applied Bio-
systems). Previous studies have reported the non-invasive
detection of SNPs [26–28] and fetal CF mutations [7,29–30] in
maternal plasma. However, the techniques used in those
publications require complicated handling to be applied in
clinical practice or are not valid to study any mutation. The great
advantage that the mini-sequencing technique presents is the
ease and rapid handling, the high sensitivity and the low cost.
Further, it gives evident results which are very important when
we are working with limited amounts of maternal plasma.
In the present study, we have carried out the genotyping of
three fetuses for the CF mutation carried by their fathers by the
SNaPshot® technique (Applied Biosystems). Since for each of
the pregnancies studied both parents were a carrier of a different
CF mutation, the presence of the paternal mutation in the
maternal plasma could only be explained by its fetal origin.
Such was the case for those maternal plasma samples collected
from cases 1 and 3. In those two cases, the paternal mutation
was detected in the plasma samples, indicating the carriercondition of the fetus for the mutation of paternal origin. In case
3 the detection of the fetal mutation was more evident in the
sample collected at the 15th weeks than the one collected in the
first trimester of gestation. These results were in accordance
with the reported increase in the amount of fetal DNA during
gestation [2,4]. Our group has previously reported a large-scale
validation study about the presence of ccffDNA in maternal
plasma in the first trimester of gestation, demonstrating the
existence of fetal DNA in all those maternal plasma samples
collected from the 7th week of gestation [16]. Since the present
work has been carried out using the same methods for collection
and DNA extraction than the aforementioned study, the absence
of the paternal mutation in the plasma sample of case 2 was
interpreted as the non-carrier status of the fetus. However, the
possibility to incorporate an independent test to validate the
presence of the fetal DNA in the plasma sample would eliminate
the risk of false negatives. In the present study this confirmation
could not be performed because of the scarcity of plasma in case
2 and the impossibility to obtain more sample from this
pregnant woman. Results obtained in the subsequent analysis of
the chorionic biopsies were in full agreement with those
obtained from the plasma samples. Therefore, based on this
criterion of presence/absence, the fetal genotype for the paternal
mutation was correctly diagnosed in all three cases, revealing
the sensitivity and robust accuracy of this technique.
This work introduces an easy-to-use and sensitive technique
for the detection of fetal mutations causing cystic fibrosis in
maternal plasma during the first trimester of pregnancy.
Through the effective exclusion of inheritance of the paternal
mutation, the need for invasive prenatal diagnostic procedures
could be eliminated in half of these pregnancies. However the
incorporation of a supplementary independent test to demon-
strate the presence of ccffDNA in the maternal plasma sample
may help to eliminate the possibility of false negatives.
Additional large-scale prospective collaborative studies will
be necessary to support these preliminary results. Once the
accuracy were widely demonstrated the field of application
could be widen and opened to the preimplantation diagnosis
field. It could be used as a confirmatory tool for those selected
embryos without the paternal mutation. In conclusion, the high
sensitivity inherent in the SNaPshot® technique makes it a
promising tool to be applied to the non-invasive prenatal
diagnosis of cystic fibrosis.
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